RÉSUMÉ
The Chemical Functional Ontology (ChemFOnt), located at https://www.chemfont.ca, is a hierarchical, OWL-compatible ontology describing the functions and actions of >341 000 biologically important chemicals. These include primary metabolites, secondary metabolites, natural products, food chemicals, synthetic food additives, drugs, herbicides, pesticides and environmental chemicals. ChemFOnt is a FAIR-compliant resource intended to bring the same rigor, standardization and formal structure to the terms and terminology used in biochemistry, food chemistry and environmental chemistry as the gene ontology (GO) has brought to molecular biology. ChemFOnt is available as both a freely accessible, web-enabled database and a downloadable Web Ontology Language (OWL) file. Users may download and deploy ChemFOnt within their own chemical databases or integrate ChemFOnt into their own analytical software to generate machine readable relationships that can be used to make new inferences, enrich their omics data sets or make new, non-obvious connections between chemicals and their direct or indirect effects. The web version of the ChemFOnt database has been designed to be easy to search, browse and navigate. Currently ChemFOnt contains data on 341 627 chemicals, including 515 332 terms or definitions. The functional hierarchy for ChemFOnt consists of four functional 'aspects', 12 functional super-categories and a total of 173 705 functional terms. In addition, each of the chemicals are classified into 4825 structure-based chemical classes. ChemFOnt currently contains 3.9 million protein-chemical relationships and â¼10.3 million chemical-functional relationships. The long-term goal for ChemFOnt is for it to be adopted by databases and software tools used by the general chemistry community as well as the metabolomics, exposomics, metagenomics, genomics and proteomics communities.
Sujet(s)
Bases de données chimiques , Logiciel , Bases de données factuelles , Gene Ontology , Génomique , ProtéomiqueRÉSUMÉ
The Human Metabolome Database or HMDB (https://hmdb.ca) has been providing comprehensive reference information about human metabolites and their associated biological, physiological and chemical properties since 2007. Over the past 15 years, the HMDB has grown and evolved significantly to meet the needs of the metabolomics community and respond to continuing changes in internet and computing technology. This year's update, HMDB 5.0, brings a number of important improvements and upgrades to the database. These should make the HMDB more useful and more appealing to a larger cross-section of users. In particular, these improvements include: (i) a significant increase in the number of metabolite entries (from 114 100 to 217 920 compounds); (ii) enhancements to the quality and depth of metabolite descriptions; (iii) the addition of new structure, spectral and pathway visualization tools; (iv) the inclusion of many new and much more accurately predicted spectral data sets, including predicted NMR spectra, more accurately predicted MS spectra, predicted retention indices and predicted collision cross section data and (v) enhancements to the HMDB's search functions to facilitate better compound identification. Many other minor improvements and updates to the content, the interface, and general performance of the HMDB website have also been made. Overall, we believe these upgrades and updates should greatly enhance the HMDB's ease of use and its potential applications not only in human metabolomics but also in exposomics, lipidomics, nutritional science, biochemistry and clinical chemistry.
Sujet(s)
Bases de données génétiques , Métabolome/génétique , Métabolomique/classification , Humains , Lipidomique/classification , Spectrométrie de masse , Interface utilisateurRÉSUMÉ
The Natural Products Magnetic Resonance Database (NP-MRD) is a comprehensive, freely available electronic resource for the deposition, distribution, searching and retrieval of nuclear magnetic resonance (NMR) data on natural products, metabolites and other biologically derived chemicals. NMR spectroscopy has long been viewed as the 'gold standard' for the structure determination of novel natural products and novel metabolites. NMR is also widely used in natural product dereplication and the characterization of biofluid mixtures (metabolomics). All of these NMR applications require large collections of high quality, well-annotated, referential NMR spectra of pure compounds. Unfortunately, referential NMR spectral collections for natural products are quite limited. It is because of the critical need for dedicated, open access natural product NMR resources that the NP-MRD was funded by the National Institute of Health (NIH). Since its launch in 2020, the NP-MRD has grown quickly to become the world's largest repository for NMR data on natural products and other biological substances. It currently contains both structural and NMR data for nearly 41,000 natural product compounds from >7400 different living species. All structural, spectroscopic and descriptive data in the NP-MRD is interactively viewable, searchable and fully downloadable in multiple formats. Extensive hyperlinks to other databases of relevance are also provided. The NP-MRD also supports community deposition of NMR assignments and NMR spectra (1D and 2D) of natural products and related meta-data. The deposition system performs extensive data enrichment, automated data format conversion and spectral/assignment evaluation. Details of these database features, how they are implemented and plans for future upgrades are also provided. The NP-MRD is available at https://np-mrd.org.
Sujet(s)
Produits biologiques/composition chimique , Bases de données factuelles , Spectroscopie par résonance magnétique , Logiciel , Produits biologiques/classification , InternetRÉSUMÉ
[This corrects the article DOI: 10.1021/acsmedchemlett.7b00485.].
RÉSUMÉ
FGF19 signaling through the FGFR4/ß-klotho receptor complex has been shown to be a key driver of growth and survival in a subset of hepatocellular carcinomas, making selective FGFR4 inhibition an attractive treatment opportunity. A kinome-wide sequence alignment highlighted a poorly conserved cysteine residue within the FGFR4 ATP-binding site at position 552, two positions beyond the gate-keeper residue. Several strategies for targeting this cysteine to identify FGFR4 selective inhibitor starting points are summarized which made use of both rational and unbiased screening approaches. The optimization of a 2-formylquinoline amide hit series is described in which the aldehyde makes a hemithioacetal reversible-covalent interaction with cysteine 552. Key challenges addressed during the optimization are improving the FGFR4 potency, metabolic stability, and solubility leading ultimately to the highly selective first-in-class clinical candidate roblitinib.
Sujet(s)
Pipérazines/composition chimique , Inhibiteurs de protéines kinases/composition chimique , Pyridines/composition chimique , Récepteur FGFR4/antagonistes et inhibiteurs , Séquence d'acides aminés , Animaux , Sites de fixation , Lignée cellulaire tumorale , Prolifération cellulaire/effets des médicaments et des substances chimiques , Cystéine/composition chimique , Chiens , Conception de médicament , Période , Hépatocytes/cytologie , Hépatocytes/effets des médicaments et des substances chimiques , Hépatocytes/métabolisme , Tumeurs du foie/traitement médicamenteux , Souris , Microsomes du foie/métabolisme , Simulation de dynamique moléculaire , Pipérazines/métabolisme , Pipérazines/pharmacologie , Pipérazines/usage thérapeutique , Inhibiteurs de protéines kinases/métabolisme , Inhibiteurs de protéines kinases/pharmacologie , Inhibiteurs de protéines kinases/usage thérapeutique , Pyridines/métabolisme , Pyridines/pharmacologie , Pyridines/usage thérapeutique , Rats , Récepteur FGFR4/métabolisme , Relation structure-activité , Tests d'activité antitumorale sur modèle de xénogreffeRÉSUMÉ
Hepatocellular carcinoma (HCC) is the most common primary malignancy of the liver and it is the third leading cause of cancer-related deaths worldwide. Recently, aberrant signaling through the FGF19/FGFR4 axis has been implicated in HCC. Here, we describe the development of FGF401, a highly potent and selective, first in class, reversible-covalent small-molecule inhibitor of the kinase activity of FGFR4. FGF401 is exquisitely selective for FGFR4 versus the other FGFR paralogues FGFR1, FGFR2, FGFR3, and all other kinases in the kinome. FGF401 has excellent drug-like properties showing a robust pharmacokinetic/pharmacodynamics/efficacy relationship, driven by a fraction of time above the phospho-FGFR4 IC90 value. FGF401 has remarkable antitumor activity in mice bearing HCC tumor xenografts and patient-derived xenograft models that are positive for FGF19, FGFR4, and KLB. FGF401 is the first FGFR4 inhibitor to enter clinical trials, and a phase I/II study is currently ongoing in HCC and other solid malignancies.
Sujet(s)
Facteurs de croissance fibroblastique/génétique , Tumeurs du foie/génétique , Tumeurs du foie/thérapie , Récepteur FGFR4/antagonistes et inhibiteurs , Animaux , Humains , Tumeurs du foie/anatomopathologie , Souris , Souris nude , Transduction du signalRÉSUMÉ
Hdm2 (human MDM2, human double minuteâ 2 homologue) counteracts p53 function by direct binding to p53 and by ubiquitin-dependent p53 protein degradation. Activation of p53 by inhibitors of the p53-Hdm2 interaction is being pursued as a therapeutic strategy in p53 wild-type cancers. In addition, HdmX (human MDMX, human MDM4) was also identified as an important therapeutic target to efficiently reactivate p53, and it is likely that dual inhibition of Hdm2 and HdmX is beneficial. Herein we report four new X-ray structures for Hdm2 and five new X-ray structures for HdmX complexes, involving different classes of synthetic compounds (including the worldwide highest resolutions for Hdm2 and HdmX, at 1.13 and 1.20â Å, respectively). We also reveal the key additive 18-crown-ether, which we discovered to enable HdmX crystallization and show its stabilization of various Lys residues. In addition, we report the previously unpublished details of X-ray structure determinations for eight further Hdm2 complexes, including the clinical trial compounds NVP-CGM097 and NVP-HDM201. An analysis of all compound binding modes reveals new and deepened insight into the possible adaptations and structural states of Hdm2 (e.g., flip of F55, flip of Y67, reorientation of H96) and HdmX (e.g., flip of H55, dimer induction), enabling key binding interactions for different compound classes. To facilitate comparisons, we used the same numbering for Hdm2 (as in Q00987) and HdmX (as in O15151, but minus 1). Taken together, these structural insights should prove useful for the design and optimization of further selective and/or dual Hdm2/HdmX inhibitors.
Sujet(s)
Protéines du cycle cellulaire/métabolisme , Composés hétérocycliques/métabolisme , Protéines proto-oncogènes c-mdm2/métabolisme , Protéines proto-oncogènes/métabolisme , Sites de fixation , Protéines du cycle cellulaire/composition chimique , Cristallographie aux rayons X , Composés hétérocycliques/composition chimique , Humains , Liaison aux protéines , Protéines proto-oncogènes/composition chimique , Protéines proto-oncogènes c-mdm2/composition chimiqueRÉSUMÉ
Small molecule inhibitors of the p53-MDM2 protein complex are under intense investigation in clinical trials as anti-cancer agents, including our first generation inhibitor NVP-CGM097. We recently described the rational design of a novel pyrazolopyrrolidinone core as a new lead structure and now we report on the synthesis and optimization of this to provide a highly potent lead compound. This new compound displayed excellent oral efficacy in our preclinical mechanistic in vivo model and marked a significant milestone towards the identification of our second generation clinical candidate NVP-HDM201.
Sujet(s)
Antinéoplasiques/pharmacologie , Multimérisation de protéines/effets des médicaments et des substances chimiques , Protéines proto-oncogènes c-mdm2/antagonistes et inhibiteurs , Pyrazoles/pharmacologie , Pyrrolidones/pharmacologie , Protéine p53 suppresseur de tumeur/antagonistes et inhibiteurs , Animaux , Antinéoplasiques/synthèse chimique , Antinéoplasiques/composition chimique , Antinéoplasiques/pharmacocinétique , Lignée cellulaire tumorale , Chiens , Haplorhini , Humains , Mâle , Souris , Microsomes du foie/métabolisme , Pyrazoles/synthèse chimique , Pyrazoles/composition chimique , Pyrazoles/pharmacocinétique , Pyrrolidones/synthèse chimique , Pyrrolidones/composition chimique , Pyrrolidones/pharmacocinétique , Rat Sprague-Dawley , StéréoisomérieRÉSUMÉ
As part of a project to identify FGFR4 selective inhibitors, scaffold morphing of a 2-formylquinoline amide hit identified series of 2-formylpyridine ureas (2-FPUs) with improved potency and physicochemical properties. In particular, tetrahydronaphthyridine urea analogues with cellular activities below 30 nM have been identified. Consistent with the hypothesized reversible-covalent mechanism of inhibition, the 2-FPUs exhibited slow binding kinetics, and the aldehyde, as the putative electrophile, could be demonstrated to be a key structural element for activity.
RÉSUMÉ
The p53-MDM2 interaction is an anticancer drug target under investigation in the clinic. Our compound NVP-CGM097 is one of the small molecule inhibitors of this protein-protein interaction currently evaluated in cancer patients. As part of our effort to identify new classes of p53-MDM2 inhibitors that could lead to additional clinical candidates, we report here the design of highly potent inhibitors having a pyrazolopyrrolidinone core structure. The conception of these new inhibitors originated in a consideration on the MDM2 bound conformation of the dihydroisoquinolinone class of inhibitors to which NVP-CGM097 belongs. This work forms the foundation of the discovery of HDM201, a second generation p53-MDM2 inhibitor that recently entered phase I clinical trial.
Sujet(s)
Découverte de médicament , Protéines proto-oncogènes c-mdm2/antagonistes et inhibiteurs , Protéine p53 suppresseur de tumeur/antagonistes et inhibiteurs , Cristallographie aux rayons X , Transfert d'énergie par résonance de fluorescence , Conformation moléculaire , Protéines proto-oncogènes c-mdm2/métabolisme , Protéine p53 suppresseur de tumeur/métabolismeRÉSUMÉ
A novel, previously undescribed 4H-thiazolo[5',4':4,5]pyrano[2,3-c]pyridine tricyclic scaffold has been discovered. The application of this novel chemotype leading to a potent and selective prototype PI3Kα inhibitor with favorable physicochemical and PK-properties is described.
Sujet(s)
Inhibiteurs des phosphoinositide-3 kinases , Inhibiteurs de protéines kinases/composition chimique , Inhibiteurs de protéines kinases/pharmacologie , Pyridines/composition chimique , Pyridines/pharmacologie , Thiazoles/composition chimique , Thiazoles/pharmacologie , Amination , Animaux , Phosphatidylinositol 3-kinases de classe I , Humains , Modèles moléculaires , Tumeurs/traitement médicamenteux , Tumeurs/enzymologie , Phosphatidylinositol 3-kinases/composition chimique , Phosphatidylinositol 3-kinases/métabolisme , Inhibiteurs de protéines kinases/pharmacocinétique , Pyridines/pharmacocinétique , Rats , Thiazoles/pharmacocinétiqueRÉSUMÉ
A cyclisation within a 4',5-bisthiazole (S)-proline-amide-urea series of selective PI3Kα inhibitors led to a novel 4,5-dihydrobenzo[1,2-d:3,4-d]bisthiazole tricyclic sub-series. The synthesis and optimisation of this 4,5-dihydrobenzo[1,2-d:3,4-d]bisthiazole sub-series and the expansion to a related tricyclic 4,5-dihydrothiazolo[4,5-h]quinazoline sub-series are described. From this work analogues including 11, 12, 19 and 23 were identified as potent and selective PI3Kα inhibitor in vivo tool compounds.
Sujet(s)
Inhibiteurs des phosphoinositide-3 kinases , Inhibiteurs de protéines kinases/composition chimique , Inhibiteurs de protéines kinases/pharmacologie , Quinazolines/composition chimique , Quinazolines/pharmacologie , Thiazoles/composition chimique , Thiazoles/pharmacologie , Animaux , Cellules Caco-2 , Phosphatidylinositol 3-kinases de classe I , Femelle , Humains , Souris nude , Modèles moléculaires , Tumeurs/traitement médicamenteux , Tumeurs/enzymologie , Phosphatidylinositol 3-kinases/composition chimique , Phosphatidylinositol 3-kinases/métabolisme , Inhibiteurs de protéines kinases/pharmacocinétique , Inhibiteurs de protéines kinases/usage thérapeutique , Quinazolines/pharmacocinétique , Quinazolines/usage thérapeutique , Relation structure-activité , Thiazoles/pharmacocinétique , Thiazoles/usage thérapeutiqueRÉSUMÉ
In recent years, the number of drug candidates with a covalent mechanism of action progressing through clinical trials or being approved by the FDA has increased significantly. And as interest in covalent inhibitors has increased, the technical challenges for characterizing and optimizing these inhibitors have become evident. A number of new tools have been developed to aid this process, but these have not gained wide-spread use. This review will highlight a number of methods and tools useful for prosecuting covalent inhibitor drug discovery programs.
Sujet(s)
Découverte de médicament , Antienzymes/pharmacologie , Enzymes/métabolisme , Animaux , Antienzymes/synthèse chimique , Antienzymes/composition chimique , Humains , Structure moléculaire , Relation structure-activitéRÉSUMÉ
CONTEXT: Hypovitaminosis D has been implicated as a possible risk factor for the development of cardiovascular disease. High-sensitivity C-reactive protein (hs-CRP) has been one of the most extensively studied biomarkers for cardiovascular inflammation as an indicator of disease and event risk, independent of traditional risk factors. To date, it is unclear if correction of hypovitaminosis D leads to a reduction of hs-CRP in human subjects. OBJECTIVES: To assess laboratory validity of 25-hydroxyvita-min D (25-OH-vitamin D) and hs-CRP measurements and to determine whether hs-CRP levels in adults with well-controlled hypertension and comorbid low vitamin D levels changed after hypovitaminosis D correction to a serum 25-OH-vitamin D level greater than 30 ng/mL. DESIGN: Prospective study using an unblinded design. RESULTS: One hundred eight subjects who were vitamin D insufficient or deficient completed this study. The mean 25-OH-vitamin D level was 20.07 ng/mL before treatment and 43.92 ng/mL after treatment. Posttreatment vitamin D levels were in the normal range for 91% of the subjects. No statistically significant changes in hs-CRP level were detected after the vitamin D treatment was administered and a posttreatment vitamin D level above 30 ng/mL was confirmed. CONCLUSION: We did not detect a statistically significant difference in hs-CRP after correction of hypovitaminosis D. Twelve weekly oral doses of 50,000 IU of ergocalciferol corrected the hypovitaminosis D in more than 90% of cases.
Sujet(s)
Protéine C-réactive/métabolisme , Maladies cardiovasculaires/sang , Hypertension artérielle/complications , Inflammation/sang , Carence en vitamine D/traitement médicamenteux , Vitamine D/usage thérapeutique , Vitamines/usage thérapeutique , Sujet âgé , Marqueurs biologiques/sang , Maladies cardiovasculaires/étiologie , Maladies cardiovasculaires/prévention et contrôle , Femelle , Humains , Inflammation/prévention et contrôle , Mâle , Adulte d'âge moyen , Études prospectives , Facteurs de risque , Vitamine D/sang , Carence en vitamine D/sang , Carence en vitamine D/complications , Vitamines/sangRÉSUMÉ
Novel nonpeptide small molecule renin inhibitors bearing an N-isopropyl P(1) motif were designed based on initial lead structures 1 and aliskiren (2). (P(3)-P(1))-Benzamide derivatives such as 9a and 34, as well as the corresponding P(1) basic tertiary amine derivatives 10 and 35 were found to display low nanomolar inhibition against human renin in vitro.
Sujet(s)
Amides/composition chimique , Antihypertenseurs/composition chimique , Benzamides/composition chimique , Éthylènes/composition chimique , Fumarates/composition chimique , Inhibiteurs de protéases/composition chimique , Rénine/antagonistes et inhibiteurs , Administration par voie orale , Animaux , Antihypertenseurs/synthèse chimique , Antihypertenseurs/pharmacologie , Benzamides/synthèse chimique , Benzamides/pharmacologie , Callithrix , Humains , Inhibiteurs de protéases/synthèse chimique , Inhibiteurs de protéases/pharmacologie , Rénine/métabolisme , Stéréoisomérie , Relation structure-activitéRÉSUMÉ
Hypertension is a major risk factor for cardiovascular diseases such as stroke, myocardial infarction, and heart failure, the leading causes of death in the Western world. Inhibitors of the renin-angiotensin system (RAS) have proven to be successful treatments for hypertension. As renin specifically catalyses the rate-limiting step of the RAS, it represents the optimal target for RAS inhibition. Several peptide-like renin inhibitors have been synthesized previously, but poor pharmacokinetic properties meant that these compounds were not clinically useful. We employed a combination of molecular modelling and crystallographic structure analysis to design renin inhibitors lacking the extended peptide-like backbone of earlier inhibitors, for improved pharmacokinetic properties. This led to the discovery of aliskiren, a highly potent and selective inhibitor of human renin in vitro, and in vivo; once-daily oral doses of aliskiren inhibit renin and lower blood pressure in sodium-depleted marmosets and hypertensive human patients. Aliskiren represents the first in a novel class of renin inhibitors with the potential for treatment of hypertension and related cardiovascular diseases.
Sujet(s)
Conception de médicament , Fumarates/composition chimique , Fumarates/pharmacologie , Hypertension artérielle/traitement médicamenteux , Rénine/antagonistes et inhibiteurs , Administration par voie orale , Adolescent , Adulte , Sujet âgé , Amides , Animaux , Pression sanguine , Cristallographie aux rayons X , Humains , Concentration en ions d'hydrogène , Concentration inhibitrice 50 , Adulte d'âge moyen , Modèles chimiques , Modèles moléculaires , Peptides/composition chimique , Rénine/sang , Rénine/composition chimique , Système rénine-angiotensine/effets des médicaments et des substances chimiques , Sodium/métabolisme , Spécificité d'espèce , Facteurs tempsRÉSUMÉ
BACKGROUND: Remote surgery requires automated sensors, effectors and sensor-effector communication. The NASA Smart Probe Project has focused on the sensor aspect. METHODS: The NASA Smart Probe uses neural networks and data from multiple microsensors for a unique tissue signature in real time. Animal and human trials use several probe configurations: (1) 8-microsensor probe (2.5 mm in diameter) for rodent studies (normal and subcutaneous mammary tumor tissues), and (2) 21-gauge needle probe with 3 spectroscopic fibers and an impedance microelectrode for breast cancer diagnosis in humans. Multisensor data are collected in real time (update 100 times/s) using PCs. RESULTS: Human data (collected by NASA licensee BioLuminate) from 15 women undergoing breast biopsy distinguished normal tissue from both benign tumors and breast carcinoma. Tumor margins and necrosis are rapidly detected. CONCLUSION: Real-time tissue identification is achievable. Potential applications, including probes incorporating nanoelectrode arrays, are presented.
Sujet(s)
Biopsie/méthodes , , Robotique , Chirurgie assistée par ordinateur , Tumeurs du sein/anatomopathologie , Systèmes informatiques , Femelle , Humains , Microélectrodes , États-Unis , NASA (USA)RÉSUMÉ
In a continuation of our efforts to simplify the structure of our neurokinin antagonists, a series of substituted biphenyl derivatives has been prepared. Several compounds exhibit potent affinities for both the NK(1) receptor (<10nM) and for the NK(2) receptor (<50 nM). Details on the design, synthesis, biological activities, SAR and conformational analysis of this new class of dual NK(1)/NK(2) receptor antagonists are presented.